Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...

Regeneron Pharmaceuticals ... the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial ...

ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent pericarditis (RP) and reduction ...

Cardiovascular diseases specialist Kiniksa Pharmaceuticals International has announced updates to its pipeline alongside ...

Of note, fourth quarter and full year 2024 collaboration expenses included a $10 million charge for Regeneron share of a $20 million milestone from Huadong Medicine with the approval of ARCALYST ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

Tarrytown, New York-based Regeneron Pharmaceuticals ... Libtayo, Evkeeza, Inmazeb Arcalyst, and Zaltrap. Zooming in further, REGN has also significantly underperformed the Health Care Select ...